Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082762 | 0.68 | NPC1 (0.42) | KDM4ENPC1RAB9AMAPTCYP1A2 | |
| SCHEMBL222947 | 0.68 | — | — | |
| SCHEMBL223116 | 0.68 | CYP1A2 (0.32) | KDM4ENPC1RAB9ACYP1A2CYP2D6 | |
| SCHEMBL1348008 | 0.67 | KDM4E (0.33) | KDM4ENPC1RAB9AMAPTCYP1A2 | |
| SCHEMBL6050750 | 0.65 | KMT2A (0.39) | NPC1RAB9AMAPTCYP1A2CYP2C9 | |
| SCHEMBL4452760 | 0.65 | CYP1A2 (0.33) | NPC1RAB9ACYP1A2CYP2D6CYP19A1 | |
| SCHEMBL4794205 | 0.65 | CYP1A2 (0.30) | NPC1RAB9ACYP1A2CYP2D6CYP19A1 | |
| SCHEMBL5930335 | 0.65 | KDM4E (0.33) | KDM4ENPC1RAB9AMAPTCYP1A2 | |
| SCHEMBL3759300 | 0.65 | MDM2 (0.31) | KDM4ENPC1RAB9AMAPTCYP1A2 | |
| SCHEMBL1932823 | 0.64 | GOT1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082823-B1 | IMINOTHIADIAZEPANE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2020-04-22 | — | — | EP | claimed |
| US-20170037056-A1 | Iminothiadiazepane Dioxide Compounds as BACE Inhibitors, Compositions, and Their Use | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | claimed |
| EP-3082823-A1 | IMINOTHIADIAZEPANE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | claimed |
| WO-2015095104-A1 | IMINOTHIADIAZEPANE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | claimed |
| EP-1963312-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007061930-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2007-05-31 | — | — | WO | claimed |
| JP-2007506696-A | — | — | 2007-03-22 | — | — | JP | claimed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | claimed |
| EP-1667980-A1 | 1,4-DISUBSTITUTED ISOQUINOLINE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2006-06-14 | — | — | EP | claimed |
| WO-2005028444-A1 | 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | claimed |
| EP-0873304-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-10-28 | — | — | EP | claimed |
| WO-1997019053-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-05-29 | — | — | WO | claimed |
| EP-3889158-B1 | FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3082823-B1 | IMINOTHIADIAZEPANE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2020-04-22 | — | — | EP | disclosed |
| US-9845482-B2 | Compositions and methods for enhancing bioenergetic status in female germ cells | THE GENERAL HOSPITAL CORPORATION (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170037056-A1 | Iminothiadiazepane Dioxide Compounds as BACE Inhibitors, Compositions, and Their Use | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| EP-0991628-B1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES | AVENTIS PHARMA INC (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2004090545-A2 | METHODS FOR TREATING PROLIFERATIVE DISEASES AND FOR MONITORING THE EFFECTIVENESS OF TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| US-5552420-A | TREATING PICORNAVIRAL INFECTIONS | STERLING WINTHROP INC. (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0217142-A2 | A polyazaheterocyclic compound | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037056-A1 | Iminothiadiazepane Dioxide Compounds as BACE Inhibitors, Compositions, and Their Use | BACE1, PSEN1, BACE2 | KDM4E 2863/4885NPC1 731/4885RAB9A 1148/4885 |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | KDM4E 1491/4885NPC1 1468/4885RAB9A 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.